A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma

被引：172
|
作者：
Popat, Rakesh [1 ,2 ]
Plesner, Torben [3 ]
Davies, Faith [4 ]
Cook, Gordon [5 ]
Cook, Mark [6 ]
Elliott, Peter [7 ]
Jacobson, Eric [7 ]
Gumbleton, Todd [1 ]
Oakervee, Heather [1 ]
Cavenagh, Jamie [1 ]
机构：
[1] St Bartholomews Hosp, London, England
[2] UCL Canc Inst, London, England
[3] Vejle Hosp, Vejile, Denmark
[4] Royal Marsden Hosp, Surrey, England
[5] St James Hosp, Leeds LS9 7TF, W Yorkshire, England
[6] Queen Elizabeth Hosp, Birmingham B15 2TH, W Midlands, England
[7] GSK Co, Sirtris, Cambridge, MA USA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2013年 / 160卷 / 05期
关键词：
myeloma; clinical trials; renal medicine; APOPTOSIS; PROTEINS;
D O I：
10.1111/bjh.12154
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：714 / 717
页数：4
相关论文
共 50 条
  • [31] RESVERATROL/SRT501 Sirtuin SIRT1 Activator Treatment of Type 2 Diabetes
    Elliott, P. J.
    Walpole, S. M.
    Morelli, L.
    Lambert, P. D.
    Lunsmann, W.
    Westphal, C. H.
    Lavu, S.
    DRUGS OF THE FUTURE, 2009, 34 (04) : 291 - 295
  • [32] Update of the results of the phase 2 CREST trial, bortezomib in refractory or relapsed multiple myeloma
    Wemeau, Mathieu
    Leleu, Xavier
    HEMATOLOGIE, 2009, 15 (01): : 7 - 8
  • [33] Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib
    Kumar, Shaji K.
    LaPlant, Betsy R.
    Reeder, Craig B.
    Roy, Vivek
    Halvorson, Alese E.
    Buadi, Francis
    Gertz, Morie A.
    Bergsagel, P. Leif
    Dispenzieri, Angela
    Thompson, Melanie A.
    Crawley, Jamie
    Kapoor, Prashant
    Mikhael, Joseph
    Stewart, Keith
    Hayman, Suzanne R.
    Hwa, Yi L.
    Gonsalves, Wilson
    Witzig, Thomas E.
    Ailawadhi, Sikander
    Dingli, David
    Go, Ronald S.
    Lin, Yi
    Rivera, Candido E.
    Rajkumar, S. Vincent
    Lacy, Martha Q.
    BLOOD, 2016, 128 (20) : 2415 - 2422
  • [34] RESULTS OF A RANDOMIZED, PHASE II STUDY OF BEVACIZUMAB AND BORTEZOMIB VS. BORTEZOMIB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: AMBER STUDY
    White, D.
    Kassim, A.
    Bhaskar, B.
    Xing, B.
    Wamstad, K.
    Paton, V.
    ANNALS OF ONCOLOGY, 2010, 21 : 351 - 352
  • [35] Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma
    Hussein, MA
    Saleh, M
    Ravandi, F
    Mason, J
    Rifkin, RM
    Ellison, R
    BRITISH JOURNAL OF HAEMATOLOGY, 2004, 125 (04) : 470 - 476
  • [36] A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma
    Richardson, Paul G.
    Blood, Emily
    Mitsiades, Constantine S.
    Jagannath, Sundar
    Zeldenrust, Steven R.
    Alsina, Melissa
    Schlossman, Robert L.
    Rajkumar, S. Vincent
    Desikan, K. Raman
    Hideshima, Teru
    Munshi, Nikhil C.
    Kelly-Colson, Kathleen
    Doss, Deborah
    McKenney, Mary L.
    Gorelik, Svetlana
    Warren, Diane
    Freeman, Andrea
    Rich, Rebecca
    Wu, Anfang
    Olesnyckyj, Marta
    Wride, Kenton
    Dalton, William S.
    Zeldis, Jerome
    Knight, Robert
    Weller, Edie
    Anderson, Kenneth C.
    BLOOD, 2006, 108 (10) : 3458 - 3464
  • [37] Vorinostat Combined with Bortezomib In Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Update on the Vantage Study Program
    Siegel, David S.
    Jagannath, Sundar
    Hajek, Roman
    Dimopoulos, Meletios A.
    Yoon, Sung-Soo
    Lonial, Sagar
    Laubach, Jacob P.
    Graef, Thorsten
    Pietrangelo, Dina
    Lupinacci, Lisa
    Reiser, David
    Anderson, Kenneth C.
    BLOOD, 2010, 116 (21) : 813 - 814
  • [38] Elotuzumab In Combination with Bortezomib In Patients with Relapsed/Refractory Multiple Myeloma: Updated Results of a Phase 1 Study.
    Jakubowiak, Andrzej J.
    Benson, Don M., Jr.
    Bensinger, William
    Siegel, David S.
    Zimmerman, Todd M.
    Mohrbacher, Ann
    Richardson, Paul G.
    Afar, Daniel E. H.
    Singhal, Anil K.
    Anderson, Kenneth C.
    BLOOD, 2010, 116 (21) : 1245 - 1245
  • [39] Phase I study of pegylated liposomal doxorubicin in combination with bortezomib for Japanese patients with relapsed or refractory multiple myeloma
    Shigeru Kusumoto
    Kazutaka Sunami
    Mitsuo Inagaki
    Shinsuke Iida
    International Journal of Hematology, 2015, 101 : 578 - 584
  • [40] PHASE I/IB STUDY OF AUY922 ALONE OR WITH BORTEZOMIB, IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
    Seggewiss-Bernhardt, R.
    Bargou, R.
    Goh, Y.
    Stewart, A.
    Spencer, A.
    Alegre, A.
    Blade, J.
    Ottmann, O.
    Akimov, M.
    Fernandez-Ibarra, C.
    Kalmady, C.
    Padmanabhan-Iyer, S.
    HAEMATOLOGICA, 2012, 97 : 346 - 346
12345